Unknown PHASE2 INTERVENTIONAL 2-arm NCT01424709

Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC) (BRAVO)

Individualized 1st Line Chemotherapy Based on BRCA1 and RRM1 mRNA Expression Levels for Advanced Non-small Cell Lung Cancer

Sponsor: Tongji University

Conditions Non-small Cell Lung Cancer

Interventions Gemcitabine, Docetaxel, CPT-11,Cisplatin gemcitabine/cisplatin

Updated 5 times since 2017 Last updated: Sep 23, 2014 Started: Dec 31, 2010 Primary completion: May 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently ongoing. Tongji University leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tongji University

Data source: Tongji University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China